Brian J. McMillan

Also affiliated with Jnana Therapeutics (United States), Io Therapeutics (United States)

MedicineImmunology and MicrobiologyBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11 -Mutant Tumors to Anti–PD-1 Immunotherapy”.

TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11 -Mutant Tumors to Anti–PD-1 Immunotherapy

Cancer Research(2025)10.1158/0008-5472.can-25-0998

N/A

0.104DataRank · unranked

1 citations

Soumyadip Sahu, Minjie Zhang, Ayushi S. Patel, Ke Geng, Reshmee Bhattacharya +47 more

Molecular basis for substrate recruitment to the PRMT5 methylosome

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.08.22.256347

N/A

0DataRank · unranked

6 citations

Christa Blomquist, Nischal Acharya, Ruitong Li, Meghan O’Keefe, Matthew J. Ranaghan +15 more

Discovery of a First-in-Class Inhibitor of the PRMT5–Substrate Adaptor Interaction

Journal of Medicinal Chemistry(2021)10.1021/acs.jmedchem.1c00507

N/A

0DataRank · unranked

52 citations

Brian J. McMillan, Matthew J. Ranaghan, Jamie A. Moroco, Merissa Brousseau, Zachary Mullin-Bernstein +18 more